

Cat. No.: GC92130

Chemical Properties

Cas. No.

SMILES [H]N[C@H](C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CO)C(N[C@H](C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@]([C@@H](C)O)([H])C(N[C@]([C@H](CC)C)([H])C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CCCCN)C(N[C@]([C@H](CC)C)([H])C(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)C(C(O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC1=CNC2=C1C=CC=C2)=O)C)=O)=O)CC3=CC=CC=C3)=O)CC(O)=O)=O)=O)C)=O)C)=O)=O)C)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)CC5=CN=CN5.CC(O)=O

Formula	C ₁₉₆ H ₃₂₃ N ₅₃ O ₅₆ ? XC ₂ H ₄ O ₂	M.Wt	4318
---------	---	------	------

Solubility	PBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml	Storage	-20°C
------------	---	---------	-------

General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
--------------	---

Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.
--------------------	--

Structure

H - His - Gly - Glu - Gly - Ser - Phe - Ser - Ser - Glu - Leu -
Ser - Thr - Ile - Leu - Asp - Ala - Leu - Ala - Ala - Arg -
Asp - Phe - Ile - Ala - Trp - Leu - Ile - Ala - Thr - Lys -
Ile - Thr - Asp - Lys - Lys - Lys - Lys - Lys - Lys - NH₂

• XCH₂CO₂H

Background

Elsiglutide is a peptide derivative of glucagon-like peptide 2 (GLP-2).¹ It increases jejunum and ileum

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@qlpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

crypt depth and villus height without disrupting gut microbiota diversity in rats when administered at a dose of 0.9 mg/kg four days per week. Elsiglutide decreases diarrhea severity and incidence induced by the dual inhibitor of EGFR and HER2 lapatinib in rats. It prevents lapatinib-induced loss of body weight in rats.

References:

[1]. Mayo, B.J., Secombe, K.R., Wignall, A.D., et al. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats *Cancer Chemother. Pharmacol.* 85(4)793-803(2020).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA